Cagrilintide vs Tesofensine
A side-by-side research comparison of Cagrilintide and Tesofensine across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cagrilintide | Tesofensine |
|---|---|---|
| Full name | Cagrilintide (AM833) | Tesofensine (Triple Monoamine Reuptake Inhibitor) |
| Category | Weight Management | Weight Management |
| Status | Investigational (Phase III) | Phase 3 Clinical Trial |
| Mechanism | Acts as a dual amylin and calcitonin receptor agonist. It engages satiety centers in the area postrema and hindbrain, reducing food intake and slowing gastric emptying through a pathway distinct from GLP-1. | Blocks presynaptic reuptake of noradrenaline, dopamine, and serotonin in the hypothalamus, enhancing satiety signaling, reducing food reward, and increasing thermogenesis. |
| Molecular weight | ~3963 Da | 329.4 Da |
| Half-life | ~7-8 days | 8-10 days |
| Bioavailability | High via subcutaneous injection | High (oral ~93%) |
| Typical dose | 0.3-2.4 mg (titrated) | 0.25-0.5 mg |
| Frequency | Once weekly | Once daily |
| Route | Subcutaneous injection | Oral |
Cagrilintide reported benefits
- Appetite suppression and increased satiety
- Meaningful weight loss
- Complements GLP-1 agonists (additive effect)
- Slows gastric emptying
Tesofensine reported benefits
- Significant appetite reduction
- Increased metabolic rate
- Improved satiety signaling
- 10-12% body weight loss
- Oral administration convenience
Related comparisons
Research and educational reference only. Not medical advice.